Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

EGM Statement

30 Jun 2008 12:12

RNS Number : 8010X
Vernalis PLC
30 June 2008
 



30 June 2008

VERNALIS PLC

RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 30 JUNE 2008

Vernalis plc announces that all resolutions proposed to shareholders at the Extraordinary General Meeting held earlier today were duly passed.

All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolution

1. To approve the sale by the Company of Apokyn® and the US Commercial Operations

143,094,025

(99.98%)

25,322

(0.02%)

7,576

2. To increase the Company's authorised share capital and to authorise the Directors to allot relevant securities 

143,060,249

(99.98%)

28,285

(0.02%)

38,389

Special Resolution

3. To authorise the Directors to allot equity securities for cash without application of statutory pre-emption rights

142,665,007

(99.72%)

403,407

(0.28%)

58,509

*NB: Percentage of votes cast excludes withheld votes

Vernalis has forwarded to the Document Viewing Facility of the Financial Services Authority two copies of the resolutions passed at the Extraordinary General Meeting. These copies will shortly be available for viewing at the Document Facility, at the address below, from 9.00am to 5.30pm on every weekday except bank holidays.

Document Viewing Facility

The Financial Services Authority

25 The North ColonadeCanary Wharf

London E14 5HS

Tel: 020 7066 1000

Printed copies of the resolutions may be obtained by writing to The Company Secretary, Vernalis plc, Oakdene Court, 613 reading Road, Winnersh, Berkshire RG41 5UA.

Enquiries:

Vernalis plc +44 (0)118 977 3133

Tony Weir, Chief Financial Officer

Brunswick Group +44 (0)20 7404 5959

Jon Coles

Justine McIlroy

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EGMBDLLLVQBLBBQ
Date   Source Headline
25th Nov 201410:13 amRNSHolding(s) in Company
18th Nov 20147:00 amRNSChange of Year End & Commercial Business Update
6th Nov 20147:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
5th Nov 201412:15 pmRNSHolding(s) in Company
5th Nov 201412:07 pmRNSHolding(s) in Company
3rd Nov 20145:06 pmRNSHolding(s) in Company
31st Oct 20145:17 pmRNSHolding(s) in Company
31st Oct 20147:00 amRNSTotal Voting Rights
27th Oct 20147:00 amRNSCTI becomes worldwide licensee for tosedostat
14th Oct 20143:55 pmRNSTransactions of Directors
10th Oct 20147:00 amRNSVernalis opens US office and strengthens US team
9th Oct 20147:00 amRNSVernalis licenses V2006 to RedoxTherapies Inc
15th Sep 20147:00 amRNSFDA accepts TuzistraTM XR NDA for full review
5th Sep 201410:30 amRNSHolding(s) in Company
29th Aug 20144:00 pmRNSTotal Voting Rights
14th Aug 201410:59 amRNSHolding(s) in Company
5th Aug 20147:00 amRNSInterim results for six months ended 30 June 2014
4th Aug 20147:00 amRNSVernalis & Servier achieve 2 Research Milestones
31st Jul 20147:00 amRNSTotal Voting Rights
22nd Jul 20147:00 amRNS3rd Product in Cough Cold Pipeline Achieves POC
17th Jul 20147:00 amRNSNotice of Results for 6 Months Ended 30 June 2014
30th Jun 20147:15 amRNSTotal Voting Rights
30th Jun 20147:00 amRNSSubmission of TuzistraTM XR (CCP-01) NDA to FDA
19th Jun 20147:00 amRNSVernalis & Servier Achieve Research Milestone
30th May 20143:30 pmRNSTotal Voting Rights
23rd May 201411:48 amRNSResult of AGM
16th May 201410:47 amRNSHolding(s) in Company
6th May 20146:16 pmRNSBLOCK LISTING SIX MONTHLY RETURN
6th May 20144:31 pmRNSHolding(s) in Company
1st May 20143:15 pmRNSHolding(s) in Company
30th Apr 20149:00 amRNSTotal Voting Rights
29th Apr 20147:00 amRNS2nd Product in Cough Cold Pipeline Achieves POC
24th Apr 20147:00 amRNSPromising Results of Ph Ib/II POC Study in ADHD
22nd Apr 20147:01 amRNSVernalis Research wins Queens Award for Enterprise
15th Apr 20147:00 amRNSNotice of Annual Report and AGM
7th Apr 20145:41 pmRNSTransactions of Directors and Applicable Employee
1st Apr 20147:00 amRNSAnnouncement of Results for year ended 31 Dec 2013
31st Mar 20144:23 pmRNSTotal Voting Rights
27th Mar 20147:00 amRNSVernalis and Asahi Kasei Pharma Achieve Milestone
6th Mar 20147:00 amRNSAppointment of Joint Broker
5th Mar 20143:00 pmRNSNotice of Results
24th Feb 20147:00 amRNSVernalis Announces Successful Completion of Study
7th Feb 20147:00 amRNSAppointment of Nominated Adviser and Broker
29th Nov 20137:00 amRNSTotal Voting Rights
25th Nov 20137:00 amRNSVernalis Announces Successful Study with CCP-01
21st Nov 20135:05 pmRNSHolding(s) in Company
6th Nov 20137:00 amRNSBlock Listing Application
1st Oct 20134:40 pmRNSSecond Price Monitoring Extn
1st Oct 20134:35 pmRNSPrice Monitoring Extension
1st Oct 20137:00 amRNSVernalis enters into research collaboration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.